Mylan’s adalimumab wins CHMP backing

A total of six biosimilar and generic medicines – three apiece – received positive opinions from the European Medicines Agency’s (EMA’s) committee for medicinal products for human use (CHMP) at its July 2018 meeting recommending the granting of marketing authorisations valid throughout the European Union (EU).  

A total of six biosimilar and generic medicines – three apiece – received positive opinions from the European Medicines Agency’s (EMA’s) committee for medicinal products for human use (CHMP) at its July 2018 meeting recommending the granting of marketing authorisations valid throughout the European Union (EU).

Mylan’s Hulio (adalimumab), developed by partner Fujifilm Kyowa Kirin Biologics, became the latest biosimilar of AbbVie’s Humira to be recommended...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin